Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma

Zhu, Hongxia; Hasan, Abdulbaqi M.E.; Liu, Rong Bin; Zhang, Zi Chen; Zhang, Xiao; Wang, Jing; Wang, Huiyun; Wang, Fang; Shao, Jian Yong

doi:10.18632/oncotarget.10082

Cited by 24 publications

(22 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study proposed that a high concentration of serum miRNA-29a-3p is associated with poor overall survival and progression-free survival in patients with HCC treated with resection or local ablation. 38 However, a contrasting study found miRNA-29 genetic (miRNA-29a-3p/b/c) expression was downregulated in HCC tissue suggesting a potential tumor suppressive role. 39 The reason for discrepancy in these results is not clear, but a deeper investigation into different miRNA-29 family members would likely explain the varied reports.…”

Section: Discussionmentioning

confidence: 99%

Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

et al. 2018

View full text Add to dashboard Cite

BackgroundWe investigated an association between the levels of plasma microRNA (miRNA)-21, -26a, and -29a-3p and treatment outcomes following transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).MethodsA total of 198 patients with TACE-treated HCC were followed up for TACE refractoriness and liver transplantation (LT)-free survival. Pretreatment plasma miRNA-21, -26a, and -29a-3p levels were measured using quantitative real-time polymerase chain reaction.ResultsDuring the mean follow-up of 22.3 (range, 0.7–79) months, 118 (59.6%) patients exhibited TACE refractoriness. Multivariate analyses showed that expression of a specific combination of miRNAs (miRNA-21 ≥ 2.5, miRNA-26a ≥ 1.5, and miRNA-29a-3p < 0.4) was associated with early TACE refractoriness (within 1 year; hazard ratio [HR], 2.32; 95% confidence interval [CI], 1.08–4.99; P = 0.031) together with tumor size (HR, 4.62; 95% CI, 1.50–14.21; P = 0.008), and macrovascular invasion (HR, 3.80; 95% CI, 1.19–12.20; P = 0.025). However, miRNA-21, -26a, and -29a-3p levels were not significantly associated with overall TACE refractoriness or LT-free survival. Additionally, large tumor size and macrovascular invasion were common predictive factor of overall TACE refractoriness and survival.ConclusionCombination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that the levels of circulating miRNAs can be significantly altered at different physiological stages and pathological conditions. Specific circulating miRNA profiles have been reported for various diseases [ 11 , 13 – 16 ]. These circulating miRNA profiles have been described to correlate with differentially expressed miRNAs in diseased tissue, such as the liver following injury by drugs [ 29 ] or a related cancer [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…Circulating miRNAs have been reported to be promising biomarkers for various pathologic conditions, including liver disease. Some miRNAs have been demonstrated to change after the initiation and progression of various liver diseases, such as CHB [ 13 , 14 ], HBC [ 15 ], and HCC [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis

et al. 2017

View full text Add to dashboard Cite

Circulating microRNAs (miRNAs) can be employed as biomarkers to diagnose liver and other diseases. Noninvasive approaches are needed to complement and improve the current strategies for screening for biomarkers liver cirrhosis. We determined whether the serum levels of miRNAs can distinguish between chronic hepatitis B (CHB) and CHB-induced cirrhosis (HBC) and investigated the potential mechanisms involved. We found that serum miR-27a was significantly up-regulated in HBC, distinguishing HBC from CHB and healthy controls (Ctrl) (P<0.0001, the area of under the curve (AUC) =0.82 and 0.87, respectively). Specifically, when miR-27a was combined with miR-122, HBC was differentiated from CHB with an AUC=0.94. The serum miR-27a level in HBC patients with hepatic decompensation was significantly higher than that in patients with compensated HBC (P=0.0009). MiR-27a was also significantly up-regulated in the serum of rats with DMN-induced liver cirrhosis compared to that in saline-treated rats (P<0.0001). Furthermore, the down-regulation of miR-27a inhibited the proliferation and overexpression of miR-27a in activated hepatic stellate cells (HSCs) through the up-regulation of α-SMA and COL1A2 expression by targeting PPARγ, FOXO1, APC, P53 and RXRα. Our study demonstrated that circulating miR-27a can be used as a predictor for the activation of HSCs and the occurrence and development of HBC.

show abstract

“…In the following year, Zhu et al discovered the role of miR-29a as a prognostic marker in HCC patients receiving surgical resection [35]. At present, growing body of evidence has shown the significance of miR-29a as a diagnostic/prognostic tool in HCC [41,42,47,50,55,[67][68][69][70] and alcoholic liver disease [71], as well as NAFLD. In 2017, Lopez-Riera et al identified circulating miR-29a as one predictor of miRNAs biomarker set in NAFLD patients [72].…”

Section: Mirs As Markers In Liver Diseasementioning

confidence: 99%

The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond

Lin

Yang

Wang

et al. 2020

Cells

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and ranges from steatosis to steatohepatitis and to liver fibrosis. Lipotoxicity in hepatocytes, elevated oxidative stress and the activation of proinflammatory mediators of Kupffer cells, and fibrogenic pathways of activated hepatic stellate cells can contribute to the development of NAFLD. MicroRNAs (miRs) play a crucial role in the dysregulated metabolism and inflammatory signaling connected with NAFLD and its progression towards more severe stages. Of note, the protective effect of non-coding miR-29a on liver damage and its versatile action on epigenetic activity, mitochondrial homeostasis and immunomodulation may improve our perception of the pathogenesis of NAFLD. Herein, we review the biological functions of critical miRs in NAFLD, as well as highlight the emerging role of miR-29a in therapeutic application and the recent advances in molecular mechanisms underlying its liver protective effect.

show abstract

Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma

Cited by 24 publications

References 43 publications

Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis

The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond

Contact Info

Product

Resources

About